Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Cytokine Release Syndrome 4Lymphoma, Non-Hodgkin 3Neoplasms, Plasma Cell 2Thrombocytosis 1Thrombocytopenia 1Schwannomatosis 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pancreatic Neoplasms 1Pain 1Neurilemmoma 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Large Granular Lymphocytic 1Immunoglobulin Light-chain Amyloidosis 1Chronic Pain 1Anemia 1Advanced Malignant Solid Neoplasm 1

Interventions

Dexamethasone 38Melphalan 20Bortezomib 18Cyclophosphamide 17Calcium Dobesilate 14Filgrastim 13daratumumab 11Peripheral Blood Stem Cell Transplantation 10pomalidomide 9Lenalidomide 8fludarabine phosphate 7dexamethasone acetate 6Whole-Body Irradiation 6Mycophenolic Acid 6Granulocyte Colony-Stimulating Factor 5Cyclosporine 5venetoclax 4ixazomib 4dexamethasone 21-phosphate 4Thalidomide 4Etoposide 4Busulfan 4auricularum 3Tacrolimus 3Radiotherapy 3Focal Adhesion Protein-Tyrosine Kinases 3Epoetin Alfa 3Doxycycline 3Darbepoetin alfa 3Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immunoglobulin Light-chain Amyloidosis × siltuximab × Clear all
NCT03315026 2025-11-04

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡